短诊断至治疗间隔与弥漫大B细胞淋巴瘤循环肿瘤DNA水平升高相关
该研究纳入欧美多中心267例弥漫大B细胞淋巴瘤患者,采用深测序个性化癌症分析检测治疗前循环肿瘤DNA水平。发现短诊断至治疗间隔与晚期疾病、高IPI及高肿瘤代谢体积相关,且治疗前ctDNA水平可独立于IPI预测短诊断至治疗间隔。ctDNA水平可客观量化基线肿瘤负荷并用于控制前瞻性临床试验的选择偏倚。
要点
- 短诊断至治疗间隔与晚期疾病和高IPI显著相关,反映基线肿瘤负荷。
- 治疗前ctDNA水平与分期、IPI及总代谢肿瘤体积均显著相关。
- 治疗前ctDNA水平可独立于IPI预测短诊断至治疗间隔。
核心结论
- 短诊断至治疗间隔主要反映基线肿瘤负荷,可通过治疗前ctDNA水平客观测量。
- 治疗前ctDNA水平有助于量化并防范前瞻性DLBCL临床试验中的选择偏倚。
研究设计与样本
- 多中心回顾性研究,纳入欧洲和美国267例接受治疗的DLBCL患者。
- 采用深测序个性化癌症分析检测治疗前ctDNA水平,并与DTI、TMTV、IPI及结局进行相关性分析。
主要发现
- 短DTI与晚期疾病相关(P < .001),与更高IPI相关(P < .001)。
- DTI与TMTV呈负相关(RS = -0.37;P < .001)。
- 治疗前ctDNA水平与分期、IPI和TMTV均显著相关(均P < .001)。
- 短DTI患者治疗前ctDNA水平更高(P < .001)。
- 治疗前ctDNA水平可独立于IPI预测短DTI(P < .001)。
关键数值与推荐
- 多变量Cox回归中,ctDNA水平对无事件生存的预后独立于DTI和IPI:ctDNA风险比1.5,95%CI [1.2 to 2.0];IPI风险比1.1,95%CI [0.9 to 1.3];-DTI风险比1.1,95%CI [1.0 to 1.2]。
临床怎么用
- 治疗前ctDNA水平可用于客观量化DLBCL基线肿瘤负荷。
- 在前瞻性DLBCL临床试验中,可利用治疗前ctDNA水平识别和防范因短DTI导致的选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with Diffuse Large B-cell Lymphoma (DLBCL) in need of immediate therapy are largely under-represented in clinical trials. The diagnosis-to-treatment interval (DTI) has recently been described as a metric to quantify such patient selection bias, with short DTI being associated with adverse risk factors and inferior outcomes. Here, we characterized the relationships between DTI, circulating tumor DNA (ctDNA), conventional risk factors, and clinical outcomes, with the goal of defining objective disease metrics contributing to selection bias. PATIENTS AND METHODS: We evaluated pretreatment ctDNA levels in 267 patients with DLBCL treated across multiple centers in Europe and the United States using Cancer Personalized Profiling by Deep Sequencing. Pretreatment ctDNA levels were correlated with DTI, total metabolic tumor volumes (TMTVs), the International Prognostic Index (IPI), and outcome. RESULTS: Short DTI was associated with advanced-stage disease (P < .001) and higher IPI (P < .001). We also found an inverse correlation between DTI and TMTV (RS = -0.37; P < .001). Similarly, pretreatment ctDNA levels were significantly associated with stage, IPI, and TMTV (all P < .001), demonstrating that both DTI and ctDNA reflect disease burden. Notably, patients with shorter DTI had higher pretreatment ctDNA levels (P < .001). Pretreatment ctDNA levels predicted short DTI independent of the IPI (P < .001). Although each risk factor was significantly associated with event-free survival in univariable analysis, ctDNA level was prognostic of event-free survival independent of DTI and IPI in multivariable Cox regression (ctDNA: hazard ratio, 1.5; 95% CI [1.2 to 2.0]; IPI: 1.1 [0.9 to 1.3]; -DTI: 1.1 [1.0 to 1.2]). CONCLUSION: Short DTI largely reflects baseline tumor burden, which can be objectively measured using pretreatment ctDNA levels. Pretreatment ctDNA levels therefore have utility for quantifying and guarding against selection biases in prospective DLBCL clinical trials.
引用
- Alig S, Macaulay CW, Kurtz DM, et al. Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2021. PMID: 33909455. doi:10.1200/JCO.20.02573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。